Amgen(AMGN) reported $19.99 billion in revenues in the nine months ended September 30,2023 and $19.4 billion in revenues in the nine months end September 30,2022.

Posted on January 5, 2024March 10, 2024 by stockanalysisLeave a comment

Investment advice We reckon that $168 per share is a good buy point. Introduction Amgen(AMGN)operate in six commercial areas: inflammation, oncology/hematology, bone health, cardiovascular (CV) disease, nephrology and neuroscience. Amgen(AMGN) conduct discovery research primarily in three therapeutic areas: inflammation, oncology/hematology and general medicine. Profitability analysis Amgen(AMGN) reported total revenues $26.2 billion, $25.9 billion and…

Stockswall

Just stock analysis.

Horizon

Amgen(AMGN) reported $19.99 billion in revenues in the nine months ended September 30,2023 and $19.4 billion in revenues in the nine months end September 30,2022.